Azithromycin/Chloroquine + Chloroquine
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Malaria, Falciparum
Conditions
Malaria, Falciparum
Trial Timeline
Aug 1, 2004 → Nov 1, 2004
NCT ID
NCT00082563About Azithromycin/Chloroquine + Chloroquine
Azithromycin/Chloroquine + Chloroquine is a phase 2 stage product being developed by Pfizer for Malaria, Falciparum. The current trial status is terminated. This product is registered under clinical trial identifier NCT00082563. Target conditions include Malaria, Falciparum.
What happened to similar drugs?
11 of 19 similar drugs in Malaria, Falciparum were approved
Approved (11) Terminated (1) Active (8)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00082563 | Phase 2 | Terminated |
Competing Products
20 competing products in Malaria, Falciparum